コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ertrophy (e.g., hypertrophic cardiomyopathy, hypertensive heart disease).
2 tion, and eventually clinical heart failure (hypertensive heart disease).
3 ifferentiate between cardiac amyloidosis and hypertensive heart disease.
4 ommunicable disease such as hypertension and hypertensive heart disease.
5 5 amyloid transthyretin, and 4 control with hypertensive heart disease.
6 d the impact of microRNA-155 manipulation in hypertensive heart disease.
7 ischemia/reperfusion, diabetes mellitus, and hypertensive heart disease.
8 of these antibodies was 17% in patients with hypertensive heart disease.
9 P overexpression and improves LV function in hypertensive heart disease.
10 ncluding ischemia/reperfusion, diabetes, and hypertensive heart disease.
11 dered metabolism that form the substrate for hypertensive heart disease.
12 tion, distinguishing HFpEF from pre-clinical hypertensive heart disease.
13 nt of heart failure symptoms in persons with hypertensive heart disease.
14 , functional, and clinical manifestations of hypertensive heart disease.
15 ntihypertensive classes and their effects on hypertensive heart disease.
16 cate that corin deficiency may contribute to hypertensive heart disease.
17 vention confers improved clinical outcome in hypertensive heart disease.
18 diastolic dysfunction very often accompanies hypertensive heart disease.
19 and functional changes associated with early hypertensive heart disease.
20 itial fibrosis resembling that seen in human hypertensive heart disease.
21 oups of participants across the continuum of hypertensive heart diseases.
22 .5 vs 5.1 deaths per 100000 persons) to 4.2 (hypertensive heart disease: 4.3 vs 17.9 deaths per 10000
25 erence was related to a greater frequency of hypertensive heart disease and congestive heart failure
26 y be applied to discriminate between HCM and hypertensive heart disease and detect early changes in G
28 ased, whereas the proportion associated with hypertensive heart disease and idiopathic fibrosis has i
30 ution in rat models of pressure overload and hypertensive heart disease and significantly attenuated
32 isease (371266 coronary heart disease, 35019 hypertensive heart disease, and 99815 other cardiovascul
33 mapping can discriminate between HCM versus hypertensive heart disease as well as to detect genetica
35 isease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease, cardiomyopathy, atrial fibri
36 nced higher mortality rates for ischemic and hypertensive heart disease compared with other subgroups
37 ed in isolated myocardium from patients with hypertensive heart disease (HHD) and heart failure with
39 bolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes, and,
41 nduced cardiac effects, we hypothesized that hypertensive heart disease is associated with oxidative
46 a predominance of nonatherosclerotic stroke, hypertensive heart disease, nonischemic and Chagas cardi
47 e with an ejection fraction <50%, those with hypertensive heart disease of the elderly, and those wit
49 ia (relative risk, 6.0; 95% CI, 4.5 to 8.1), hypertensive heart disease (relative risk, 2.4; 95% CI,
51 ath, including prostate cancer, myeloma, and hypertensive heart disease, the higher death rates among
52 Mechanisms promoting the transition from hypertensive heart disease to heart failure with preserv
53 ortant for clinicians to identify and manage hypertensive heart disease to prevent increased morbidit
54 nfarction and trauma but not cardiomyopathy, hypertensive heart disease, valvular heart disease, cere
55 tissue volume fraction in a rodent model of hypertensive heart disease, whereas the widely used anal
56 rtic constriction mice displayed compensated hypertensive heart disease with hypertrophy, increased o
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。